Capricor Therapeutics, Inc. (CAPR) Q1 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights significant progress in product development, strategic partnerships, and financial performance. Positive interim results in the Phase III trial, increased revenue, and reduced net loss are notable. The Q&A reveals confidence in regulatory strategies and strong safety profiles, despite some uncertainties. The potential for milestone payments and global expansion, along with a strong cash position, supports a positive outlook. However, increased R&D expenses and lack of specific guidance on milestone triggers and partnerships temper enthusiasm slightly. Overall, the stock is likely to see a positive movement in the short term.
Key Financial Performance
Cash Position $39.9 million (up from $39.5 million) year-over-year change: +$0.4 million; reason for change: receipt of a $10 million milestone payment from Nippon Shinyaku and $3.5 million raised under at-the-market program.
Research and Development Expense $10.1 million (up from $7.2 million) year-over-year change: +$2.9 million; reason for change: increased clinical and manufacturing costs associated with the Phase 3 HOPE-3 clinical trial.
General and Administrative Expense $1.8 million (no change from Q1 2023) year-over-year change: 0%; reason for change: consistent expenses year-over-year.
Net Loss $9.8 million (up from $7.8 million) year-over-year change: +$2 million; reason for change: increased expenses primarily in research and development.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
CAP-1002: CAP-1002 is a cardiac cell therapy for Duchenne Muscular Dystrophy (DMD) with a focus on clinical, manufacturing, BLA readiness, and commercial preparations.
HOPE-3 Trial: Enrollment completed in Cohort A with 61 subjects; positive interim analysis triggered a $10 million milestone payment from Nippon Shinyaku.
Cohort B: FDA no longer requires data from Cohort B for manufacturing site transition, allowing faster BLA submission.
Exosome Platform: Progress on StealthX engineered exosome delivery platform, targeting a product in the clinic by end of 2024.
Market Expansion: Plans to expand Cohort B to include European patients and discussions with EMA for a global trial.
Commercialization: Increased meetings with Nippon Shinyaku for potential commercialization of CAP-1002 in the US and Japan.
Manufacturing Efficiency: San Diego facility operational and producing doses for clinical use; plans for commercial runs underway.
Financial Position: Cash position of approximately $39.9 million; received $10 million milestone payment.
Regulatory Strategy: Type B meeting with FDA scheduled to align on BLA submission and rolling review process.
Revenue Model: Revenue share agreement with Nippon Shinyaku includes mid-range double-digit share of product revenue.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company is preparing for a Type B meeting with the FDA to align on the path to a Biologics License Application (BLA) submission. The outcome of this meeting is critical for the approval process.
Manufacturing Risks: Transitioning to the San Diego manufacturing facility without additional clinical data was a significant win, but any future expansion will depend on market demand and resource availability.
Financial Risks: The company has a cash position of approximately $39.9 million, which is expected to last into Q1 2025, excluding potential milestone payments. Increased R&D expenses due to clinical trials may impact financial stability.
Competitive Pressures: The company is actively discussing potential label expansions and partnerships in Europe, indicating competitive pressures in the market for DMD treatments.
Supply Chain Challenges: The company is focused on ensuring manufacturing capabilities to meet projected market demand, which may pose challenges if demand exceeds expectations.
Economic Factors: The company aims to price CAP-1002 competitively against existing therapies, which may be influenced by payer interactions and market conditions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Core Areas of Focus: Capricor is focused on four main areas: clinical, manufacturing, BLA readiness, and commercial preparations for CAP-1002.
HOPE-3 Trial Update: Enrollment for Cohort A of the HOPE-3 trial was completed with 61 subjects, and top-line data is expected in late 2024.
Milestone Payment: Received a $10 million milestone payment from Nippon Shinyaku triggered by a positive interim analysis.
Manufacturing Transition: FDA no longer requires data from Cohort B to support the transition to the San Diego manufacturing facility.
Commercialization Preparations: Increased meetings with Nippon Shinyaku to prepare for potential commercialization of CAP-1002.
Revenue Model: Capricor will receive a transfer price and a mid-range double-digit share of product revenue from Nippon Shinyaku.
Market Demand: Plans to expand the San Diego facility based on market demand for CAP-1002.
Global Growth Opportunities: Active discussions for European rights for CAP-1002 and potential label expansion.
Exosome Platform Development: Targeting to have an exosome-based product in the clinic by the end of 2024.
Cash Position: As of March 31, 2024, cash and equivalents totaled approximately $39.9 million.
Cash Runway: Expect cash runway to extend into Q1 2025, excluding additional milestone payments.
R&D Expenses: Q1 2024 R&D expenses were approximately $10.1 million, up from $7.2 million in Q1 2023.
Net Loss: Net loss for Q1 2024 was approximately $9.8 million, compared to $7.8 million in Q1 2023.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Milestone Payment: Received a $10 million milestone payment from Nippon Shinyaku under the exclusive distribution and commercialization agreement.
Potential Milestone Payments: Eligible for an additional $90 million in potential milestone payments up to the time of approval, triggered upon certain regulatory-based achievements.
Revenue Share: Under the US distribution agreement with Nippon Shinyaku, Capricor will receive a transfer price for each dose sold and a mid-range double-digit share of product revenue, estimated between 30% and 50%.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Is it fair to say that there's a trigger that could occur if you have positive data in the fourth quarter?
A:We're not at liberty to announce yet sort of the tenor of the milestone payments, but suffice it to say that we plan on them being able to strengthen our balance sheet as we move from approval through BLA.
Q:Can you remind us of what the latest interaction has been with any regulatory agency ex US?
A:We've had some initial reach-outs, mostly through our consultants, in terms of strategizing to how to approach both the EMA and then the Japan regulatory authorities, the PMDA. Europe has significantly less therapeutics approved in Duchenne muscular dystrophy than the United States.
Q:What do you think it is that the investment community is missing out, considering it's a late-stage asset with some data already in place?
A:We have a late-stage asset. We have really lovely clinical data that's been supported by publication in the highest-ranked journals. It's a little bit elusive why we haven't caught fire.
Q:What are my costs to make this or what cost of goods sold could ultimately be assuming premium pricing in this orphan disease?
A:We're still sort of firing away here manufacturing and trying to come up with some final numbers. We believe that the costs will be relatively minimal compared to what we're going to be able to get in reimbursement for this product.
Q:Should we be looking for the same type of approximate deal structure as NS? Or are you looking at various options?
A:I can't reveal the types of deals that we are pursuing right now nor the analysis that we're doing internally as to whether we would take this forward independently.
Q:What would be the endpoint and its sort of underlying benchmark that we in the investment community should look for?
A:Looking like some of the traditional secondary cardiac endpoints that adult heart disease has been looking at for a long time, ejection fraction and volumes.
Q:Could you share with us any feedback related to this apparent enthusiasm of physicians and patients?
A:The rapid enrollment speaks for itself. There's nothing for these guys, literally nothing. The physician leaders know that what is most important to these boys and young men is the preservation of upper limb function.
Q:Could you give us any updates on possible preclinical or preparation work you do as it relates to Becker muscle dystrophy?
A:We're looking at Becker dystrophy as well as other types of neurodegenerative diseases that are characterized by inflammation and fibrosis.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the specific deal structure for potential partnerships, stating they cannot reveal the types of deals they are pursuing. Additionally, they did not provide clear cost of goods sold figures, indicating they are still working on final numbers.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ARG
American Society
Becker dystrophy
CAP DMD
CAP treatment
CMC
Capricor
Cohort
Diego manufacturing
HOPE label
NIAID
Nippon Shinyaku
age
analysis
approach
area
assay
asset
cost
deal
distribution
energy
enthusiasm
estimate
exon
exosomes
gene
heart
label extension
limb function
meeting FDA
partner
path
price
reimbursement
safety efficacy
sense
share
subject
submission
transition
type
update preparation
week
CAPR Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call reveals significant financial challenges, including a net loss increase and zero revenue for Q1 2025, raising concerns about financial sustainability. Despite a strong cash position and potential milestone payments, extended negotiations and increased expenses further contribute to a negative outlook. The Q&A session highlighted uncertainties in regulatory progress and market entry delays. Overall, the financial struggles and uncertainties outweigh the potential positive impacts, leading to a negative sentiment rating.
Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript
Neutral11-14
The earnings call summary presents mixed signals. The financial performance shows a significant revenue decline and increased losses, which is concerning. However, the strong cash position and potential milestone payments from a European agreement are positive. The Q&A section highlights readiness for market launch and manufacturing capabilities, but there are uncertainties in trial designs and management responses. The public offering and cash position are positive, but the revenue decline and increased expenses dampen the overall sentiment, leading to a neutral prediction with potential for positive movement if milestones are achieved.
Capricor Therapeutics, Inc. (CAPR) Q2 2024 Earnings Call Transcript
Neutral8-9
Capricor Therapeutics, Inc. (CAPR) Q1 2024 Earnings Call Transcript
Positive5-14
The earnings call highlights significant progress in product development, strategic partnerships, and financial performance. Positive interim results in the Phase III trial, increased revenue, and reduced net loss are notable. The Q&A reveals confidence in regulatory strategies and strong safety profiles, despite some uncertainties. The potential for milestone payments and global expansion, along with a strong cash position, supports a positive outlook. However, increased R&D expenses and lack of specific guidance on milestone triggers and partnerships temper enthusiasm slightly. Overall, the stock is likely to see a positive movement in the short term.
CAPR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
